Vahid Rahanfar

First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer.

S. Behr, Youngho Seo, H. VanBrocklin, 2017 .